MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MTR | 5-methyltetrahydrofolate-homocysteine methyltransferase | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Expressed in all |
PDE7A | Phosphodiesterase 7A | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Expressed in all |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PLA2G1B | Phospholipase A2, group IB (pancreas) | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
PLG | Plasminogen | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PNLIP | Pancreatic lipase | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PNP | Purine nucleoside phosphorylase | Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
PROC | Protein C (inactivator of coagulation factors Va and VIIIa) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PROS1 | Protein S (alpha) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PSMD1 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
QPRT | Quinolinate phosphoribosyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
REN | Renin | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
RPL3 | Ribosomal protein L3 | FDA approved drug targets Plasma proteins Predicted secreted proteins Ribosomal proteins
| | | | | Expressed in all |
SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
SERPINC1 | Serpin peptidase inhibitor, clade C (antithrombin), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SERPIND1 | Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
SLC8A1 | Solute carrier family 8 (sodium/calcium exchanger), member 1 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
TFPI | Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) | Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
TNFRSF8 | Tumor necrosis factor receptor superfamily, member 8 | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
TOP1MT | Topoisomerase (DNA) I, mitochondrial | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Expressed in all |
TPO | Thyroid peroxidase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
TSHR | Thyroid stimulating hormone receptor | Cancer-related genes Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
VEGFA | Vascular endothelial growth factor A | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
VWF | Von Willebrand factor | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Mixed |